1 Lansiaux A, Facompre M, Wattez N, Hildebrand MP, Bal C, Demarquay D, et al.Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL-60 cells[J].Mol Pharmacol, 2001;60:450-61 2 Philippart P, Harper L, Chaboteaux C, Decaestecker C, Bronckart Y, Gordover L, et al.Homocamptothecin, an E-ringmodified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions[J].Clin Cancer Res, 2000;6:1557-62 3 Yang Y, Li CC, Weissman AM.Regulating the p53 sy stem through ubiquitination[J].Oncogene, 2004;23:2096-106 4 Kim KW, Kim BJ, Chung CW, Jo DG, Kim IK, Song YH, et al.Caspase cleavage product lacking amino-terminus of IkappaBalpha sensitizes resistant cells to TNF-alpha and TRAIL-induced apoptosis[J].J Cell Biochem, 2002;85:334-45 5 Gupta S, Afaq F, Mukhtar H.Involvement of nuclear factorkappa B, Bax and Bcl-2 in induction of cell cy cle arrest and apoptosis by apigenin in human prostate carcinoma cells[J].Oncogene, 2002;21:3727-38 6 Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS.p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition[J].Oncogene, 2004; 23:1283-90 7 Ho J, Benchimol S.Transcriptional repression mediated by the p53 tumour suppressor[J].Cell Death Differ, 2003;10:404-8 8 Gartel AL, Tyner AL.The role of the cyclin-dependent kinase inhibitor p21 in apoptosis[J].Mol Cancer Ther, 2002;1:639-49 9 Cory S, Huang DC, Adams JM.The Bcl-2 family:roles in cell survival and oncogenesis[J].Oncogene, 2003;22:8590-607 |